Nascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0948 USD | +5.33% | -5.01% | -45.17% |
1st Jan change | Capi. | |
---|---|---|
-45.17% | 16.17M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- NBIO Stock
- News Nascent Biotech, Inc.
- Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer